Analysis of gene expression profiles in an imatinib-resistant cell line, KCL22/SR

Stem Cells

Volumn 21, Issue 3, 2003, Pages 315-321

  Ohmine, Ken ^a   Nagai, Tadashi ^a   Tarumoto, Takahisa ^a   Miyoshi, Takuji ^a   Muroi, Kazuo ^a   Mano, Hiroyuki ^a   Komatsu, Norio ^a   Takaku, Fumimaro ^a   Ozawa, Keiya ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Drug resistance; Imatinib mesylate; KCL22 SR; MAPK; Ras

Indexed keywords

ACTIVIN A; BCR ABL PROTEIN; GLYCOPROTEIN P; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P21; RAS PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; TUMOR ANTIGEN;

ARTICLE; BLAST CELL CRISIS; CANCER CELL CULTURE; CANCER RECURRENCE; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; DNA MICROARRAY; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; IC 50; ONCOGENE C MYB; PROTEIN PHOSPHORYLATION; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION;

EID: 0038362176     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1634/stemcells.21-3-315     Document Type: Article

References (28)

1. Druker BJ, Talpaz M, Resta DJ et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-1037.
2. Druker BJ, Sawyers CL, Kantarjian H et al. Activity of a specific inhibitor of the BCR/ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-1042.
3. le Coutre P, Tassi E, Varella-Garcia M et al. Induction of resistance to the Abelson inhibitor ST1571 in human leukemic cells through gene amplification. Blood 2000;95:1758-1766.
4. Weisberg E, Griffin JD. Mechanism of resistance to the ABL tyrosine kinase inhibitor ST1571 in BCR/ABL-transformed hematopoietic cell lines. Blood 2000;95:3498-3505.
5. Mahon FX, Deininger MW, Schultheis B et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor ST1571: diverse mechanisms of resistance. Blood 2000;96:1070-1079.
6. Gorre ME, Mohammed M, Ellwood K et al. Clinical resistance to ST1571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-880.
7. Branford S, Rudzki Z, Walsh S et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (ST1571) resistance. Blood 2002;99:3472-3475.
8. Gambacorti-Passerini C, Barni R, le Coutre P et al. Role of alphal acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor ST1571. J Natl Cancer Inst 2002;92:1641-1650.
9. Kubonishi I, Miyoshi I. Establishment of a Ph1 chromosomepositive cell line from chronic myelogenous leukemia in blast crisis. Int J Cell Cloning 1983;1:105-117.
10. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-159.
11. Nagai T, Igarashi K, Akasaka J et al. Regulation of NF-E2 activity in erythroleukemia cell differentiation. J Biol Chem 1998;273:5358-5365.
12. Ohmine K, Ota J, Ueda M et al. Characterization of stage progression in chronic myeloid leukemia by DNA microarray with purified hematopoietic stem cells. Oncogene 2001;20:8249-8257.
13. Kumar S, Vinci JM, Pytel BA et al. Expression of messenger RNAs for complement inhibitors in human tissues and tumors. Cancer Res 1993;53:348-353.
14. Kantarjian HM, Talpaz M, Imatinib mesylate: clinical results in Philadelphia chromosome-positive leukemias. Semin Oncol 2001;28(suppl 17):9-18.
15. Motoji T, Motomura S, Wang YH. Multidrug resistance of acute leukemia and a strategy to overcome it. Int J Hematol 2000;72:418-424.
16. Leith CP, Kopecky KJ, Chen IM et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-gp, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood 1999;94:1086-1099.
17. van der Kolk DM, de Vries EG, Noordhoek L et al. Activity and expression of the multidrug resistance proteins P-glycoprotein, MRP1, MRP2, MRP3 and MRP5 in de novo and relapsed acute myeloid leukemia. Leukemia 2001;15:1544-1553.
18. Pirker R, Pohl G, Stranzl T et al. The lung resistance protein (LRP) predicts poor outcome in acute myeloid leukemia. Adv Exp Med Biol 1999;457:133-139.
19. Trahey M, Wong G, Halenbeck R et al. Molecular cloning of two types of GAP complementary DNA from human placenta. Science 1988;242:1697-1700.
20. Maekawa M, Ishizaki T, Boku S et al. Signaling from Rho to the actin cytoskeleton through protein kinases ROCK and LIM-kinase. Science 1999;285:895-898.
21. 1 phase of the cell cycle. Oncogene 1993;8:1449-1455.
22. Sahai E, Olson MF, Marshall CJ. Cross-talk between Ras and Rho signalling pathways in transformation favours proliferation and increased motility. EMBO J 2001;20:755-766.
23. Qiu RG, Chen J, Kim D et al. An essential role for Rac in Ras transformation. Nature 1995;374:457-459.
24. Qiu RG, Chen J, McCormick F et al. A role for Rho in Ras transformation. Proc Natl Acad Sci USA 1995;92:11781-11785.
25. Marken JS, Schieven GL, Hellstrom I et al. Cloning and expression of the tumor-associated antigen L6. Proc Natl Acad Sci USA 1992;89:3503-3507.
26. Mucenski ML, McLain K, Kier AB et al. A functional c-myb gene is required for normal murine fetal hepatic hematopoiesis. Cell 1991;65:677-689.
27. Miglarese MR, Richardson AF, Aziz N et al. Differential regulation of c-Myb-induced transcription activation by a phosphorylation site in the negative regulatory domain. J Biol Chem 1996;271:22697-22705.
28. ten Dijke P, Franzen P, Yamashita H et al. Serine/threonine kinase receptors. Prog Growth Factor Res 1994;5:55-72.